Evidence map›Paper›PMID 39109867›Full record

ArticlemBio2024

Enhancing immunity against

Ahmed Rishiq, Mingdong Liu, Ofer Mandelboim

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ahmed RishiqThe Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), Hebrew University-Hadassah Medical School, Jerusalem, Israel.ORCID 0000-0001-6564-1050
Mingdong LiuThe Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Ofer MandelboimThe Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), Hebrew University-Hadassah Medical School, Jerusalem, Israel.ORCID 0000-0002-9354-1855

Funding

Cytovia Therapeutics Holdings 6-2020-22652German-Israeli Foundation for Scientific Research and Development (GIF) 1412-414.13/2017Integra Holdings LTD 11-2020-22710Israel Science Foundation (ISF) ISF Israel-China grant 2554/18Israel Science Foundation (ISF) Moked grant 442-18, 3042/22, 619/23Ministry of Economy (Israel) | Israel Innovation Authority (IIA) 62615, 72670, 75934Ministry of Science and Technology of the People's Republic of China (MOST) 3-14764MOST-DKFZ grant 3-14931The Rothschild Foundation
6 · The paper itself

Abstract

T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is an inhibitory receptor expressed by T and natural killer cells. Here, we used TIGIT knockout (KO) mice to demonstrate that mouse TIGIT directly interacts with IMPORTANCE: Our results identify the significance of T cell immunoreceptor with immunoglobulin and ITIM domain in modulating host defense against

Indexed as

Candida albicansCandidiasisReceptors, ImmunologicAnimalsLigandsMiceMice, Inbred C57BLMice, KnockoutLigandsReceptors, ImmunologicT cell Ig and ITIM domain protein, mouseagglutinin-like sequencesCandida albicansfusion proteinsystemic candidiasisTIGIT knockout

Identifiers

PMID39109867
PMCPMC11389390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.